MedTrace Logo

Effect of Astaxanthin Supplementation on Plasma Malondialdehyde Levels and NIHSS of Stroke Patients

NCT03945526 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-05-13

No results posted yet for this study

Summary

This is an interventional randomized, controlled trial in analyzing the effects of astaxanthin supplementation on plasma malondialdehyde levels and NIHSS of acute ischemic stroke patients. According to published studies, it was hypothesized that acute ischemic stroke patients who were given astaxanthin would have lower plasma malondialdehyde levels and lower NIHSS score compared to the control group.

Conditions

  • Cerebral Stroke
  • Malondialdehyde
  • Oxidative Stress

Interventions

DRUG

Astaxanthine

DRUG

Placebo Oral Tablet

Sponsors & Collaborators

  • Indonesia University

    lead OTHER

Principal Investigators

  • Salim Harris, SpS · IDI

  • Sri Sukmaniah, SpGK · IDI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-23
Primary Completion
2010-06-09
Completion
2010-06-09

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03945526 on ClinicalTrials.gov